Suppr超能文献

褪黑素、选择性和非选择性 MT1/MT2 受体激动剂:对 24 小时警觉状态的差异影响。

Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.

机构信息

Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University Health Center, McGill University, Montreal, QC, Canada.

Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, PU, Italy.

出版信息

Neurosci Lett. 2014 Feb 21;561:156-61. doi: 10.1016/j.neulet.2013.12.069. Epub 2014 Jan 7.

Abstract

Melatonin (MLT) is a neurohormone implicated in several physiological processes such as sleep. Contrasting results have been produced on whether or not it may act as a hypnotic agent, and the neurobiological mechanism through which it controls the vigilance states has not yet been elucidated. In this study we investigated the effect of MLT (40 mg/kg), a non-selective MT1/MT2 receptor agonist (UCM793, 40 mg/kg), and a selective MT2 partial agonist (UCM924, 40 mg/kg) on the 24-h vigilance states. EEG and EMG sleep-wake patterns were registered across the 24-h light-dark cycle in adult Sprague-Dawley male rats. MLT decreased (-37%) the latency to the first episode of non rapid eye movement sleep (NREMS), enhanced the power of NREMS delta band (+33%), but did not alter the duration of any of the three vigilance states. Differently, UCM793 increased the number of episodes (+52%) and decreased the length of the episodes (-38%) of wakefulness but did not alter the 24-h duration of wakefulness, NREMS and REMS. UCM924 instead reduced the latency (-56%) and increased (+31%) the duration of NREMS. Moreover, it raised the number of REMS episodes (+57%) but did not affect REMS duration. Taken together, these findings show that MLT and non-selective MT1/MT2 receptor agonists do not increase the quantity of sleep but differently influence the three vigilance states. In addition, they support the evidence that selective MT2 receptor agonists increase NREMS duration compared to MLT and non-selective MT1/MT2 agonists.

摘要

褪黑素(MLT)是一种神经激素,参与多种生理过程,如睡眠。关于它是否可以作为催眠剂,以及它控制警觉状态的神经生物学机制,结果却相互矛盾。在这项研究中,我们研究了 MLT(40mg/kg)、非选择性 MT1/MT2 受体激动剂(UCM793,40mg/kg)和选择性 MT2 部分激动剂(UCM924,40mg/kg)对 24 小时警觉状态的影响。在成年 Sprague-Dawley 雄性大鼠的 24 小时明暗周期中,记录了 EEG 和 EMG 睡眠-觉醒模式。MLT 降低了(-37%)非快速眼动睡眠(NREMS)的首次发作潜伏期,增强了 NREMS 的δ波段功率(+33%),但未改变任何三种警觉状态的持续时间。相反,UCM793 增加了觉醒(+52%)的发作次数,并缩短了觉醒(-38%)的持续时间,但未改变觉醒、NREMS 和 REMS 的 24 小时持续时间。UCM924 则减少了(-56%)潜伏期并增加(+31%)了 NREMS 的持续时间。此外,它增加了 REMS 发作次数(+57%),但未影响 REMS 持续时间。综上所述,这些发现表明,MLT 和非选择性 MT1/MT2 受体激动剂不会增加睡眠时间,但会以不同的方式影响三种警觉状态。此外,它们支持选择性 MT2 受体激动剂与 MLT 和非选择性 MT1/MT2 激动剂相比,增加 NREMS 持续时间的证据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验